培训课件--NCCN胃癌临床实践指南中国版解读.pptVIP

* A superior response rate was observed for Xeloda/cisplatin vs. 5-FU/cisplatin (p=0.030), supporting the general trend to superiority seen in other efficacy endpoints. Tumor responses were assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) specifications. Overall response is the sum of confirmed complete and partial responses. Three complete responses were observed in Xeloda/cisplatin groups vs. 4 complete responses in the 5-FU/cisplatin group. Patients in the Xeloda/cisplatin group had 1.4 times the chance of achieving an overall response compared to patient